Neal Sharpe

Neal Sharpe, PhD, currently serves as Vice President of Nonclinical Optimization and Development at Biohaven, where responsibilities include overseeing toxicology, DMPK, and preclinical development to align with clinical and regulatory needs. With extensive experience in toxicology and preclinical safety, Neal has held key positions including Executive Director at Biohaven, Principal at NA Sharpe Pharma, Vice President of Translational Sciences at Eloxx Pharmaceuticals, and Director roles at Biogen Idec and Merck. Neal's educational background includes a PhD in Neurobiology and Neurosciences from Rutgers University and advanced degrees in Biology and Physiology from William Paterson University.